Print Page  Close Window

2019 News Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
03/19/19Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of AnthraxDownload PDFPrinter Friendly Version
02/28/19Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare AgentsDownload PDFPrinter Friendly Version
02/21/19Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial ResultsDownload PDFPrinter Friendly Version
02/12/19Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of DirectorsDownload PDFPrinter Friendly Version
02/07/19Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019Download PDFPrinter Friendly Version
01/24/19Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of DirectorsDownload PDFPrinter Friendly Version
01/07/19Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial ForecastDownload PDFPrinter Friendly Version
01/04/19Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEODownload PDFPrinter Friendly Version